Abstract [View PDF] [Read Full Text]
With the introduction of landmark genetic product, Luxturna, into clinical application in 2017, gene therapy is rapidly developed in ophthalmology.Clinical researches and practices have confirmed that subretinal injection technique is one of the important intraocular delivery approaches for gene therapy drugs related to inherited retinal diseases (IRDs) and other fundus diseases.The technique is characterized by the addition of unique drug delivery operation on the basis of vitreoretinal surgery, so that the therapeutic gene can precisely accumulate in the target area and act on the target cells.The efficacy of gene therapy, distribution of viral vector and degree of immune response mainly depend on the safe and efficient delivery of drugs into the subretinal space.There is a large number of patients with IRDs and other fundus diseases in China.Although gene therapy has just started, it has attracted great attention at home and overseas.Thus, it is necessary to develop a detailed and complete operative standard for subretinal injection of gene therapy according to the current research evidence and clinical practices worldwide.This expert consensus may standardize the surgical procedure of clinicians and facilitate the development of gene therapy related to IRDs and other fundus diseases.With the development of genetic technology, the relevant content will be constantly updated in future.